BMC Medical Research Methodology

Table 2 Comparison between three optimal designs for expected sample size ESS₀ at α=0.05 given π_a−π_u=0.2 and 0.15

From: Minimax and admissible adaptive two-stage designs in phase II clinical trials

			Minimax						Optimal
			Simon		Minimax-EF		Adaptive		Adaptive
π _u	π _a	Power	n	E S S ₀	n	E S S ₀	n	E S S ₀	n	E S S ₀
π_a−π_u=20 %
0.1	0.3	0.8	25	19.51	24	20.30	23	20.94	29	14.85
		0.9	33	26.18	33	23.96	33	23.93	35	22.38
0.2	0.4	0.8	33	22.25	32	24.93	32	23.22	37	20.48
		0.9	45	31.23	44	35.68	44	33.39	53	29.74
0.3	0.5	0.8	39	25.69	36	30.68	36	29.31	46	23.45
		0.9	53	36.62	50	42.47	50	41.03	60	34.08
0.4	0.6	0.8	39	34.44	39	34.33	39	26.86	46	24.39
		0.9	54	38.06	54	38.03	53	42.65	66	35.64
0.5	0.7	0.8	37	27.74	37	26.90	37	26.87	43	23.33
		0.9	53	36.11	51	41.14	51	37.74	59	33.45
0.6	0.8	0.8	35	20.77	33	23.97	33	22.13	38	20.28
		0.9	45	35.90	45	33.30	45	31.36	52	28.74
0.7	0.9	0.8	26	23.16	26	23.11	25	18.00	27	14.82
		0.9	32	22.66	32	22.66	32	22.64	36	20.80
π_a−π_u=15 %
0.1	0.25	0.8	40	28.84	38	33.94	38	28.87	43	24.49
		0.9	55	40.03	53	47.87	53	41.29	62	36.45
0.2	0.35	0.8	53	40.44	53	40.41	53	40.33	63	34.87
		0.9	77	58.42	76	66.51	74	59.58	87	50.80
0.3	0.45	0.8	65	49.63	64	51.32	64	48.08	77	41.33
		0.9	88	78.51	88	78.45	88	68.29	104	59.96
0.4	0.55	0.8	70	60.07	69	54.17	69	49.84	82	44.05
		0.9	94	78.88	94	76.30	94	74.20	106	63.84
0.5	0.65	0.8	68	66.11	68	66.05	67	58.41	81	43.01
		0.9	93	75.00	93	72.20	93	69.84	109	61.87
0.6	0.75	0.8	62	43.79	62	42.89	61	45.26	69	38.53
		0.9	84	73.20	84	73.13	84	64.00	97	54.99
0.7	0.85	0.8	49	34.44	49	34.36	49	33.00	59	29.78
		0.9	68	48.52	65	50.46	65	48.78	78	42.60

Back to article page

ISSN: 1471-2288

Contact us

General enquiries: journalsubmissions@springernature.com